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ABSTRACT
Nonmalignant late effects, including chronic renal failure (CRF), impair the quality of life of long-term
survivors after allogeneic hematopoietic cell transplantation. One of the major risk factors is the use of total
body irradiation (TBI) in the preparative regimen; TBI is currently fractionated in an attempt to reduce
toxicity. We analyzed 241 patients who had TBI-based preparative regimens for allogeneic hematopoietic cell
transplantation. TBI was delivered as a single fraction of 7.5 Gy (7.5S group), 12 Gy in 6 fractions (12F group),
or 14.4 Gy in 8 fractions (14.4F group). The cumulative incidence of CRF at 2 years was 12%. Statistical
analysis revealed that older age (P < .001) and fludarabine administration (P  .016) had a significant effect on
the incidence of CRF. Furthermore, single-fraction TBI was also significantly associated with CRF severity,
because 7 (6.3%) of 111 patients in the 7.5S group developed severe CRF, as opposed to 1 (0.8%) of 130
patients in the 12F and 14.4F groups combined (P  .044). However, these conclusions should be regarded as
preliminary in view of the retrospective and nonrandomized nature of this study.
© 2006 American Society for Blood and Marrow Transplantation
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iNTRODUCTION
Allogeneic hematopoietic cell transplantation
HCT) after high-dose chemotherapy and total body
rradiation (TBI) is a widely accepted therapeutic ap-
roach for several hematologic malignancies [1].
any patients currently enjoy long-term survival after
CT, and late clinical effects are therefore of major
oncern. Secondary malignancies are usually a conse-
uence of immunosuppression, high-dose chemother-
py, TBI, or a combination of these [2,3]. Nonmalig-
ant late effects, although rarely life-threatening,
igniﬁcantly impair the quality of life of long-term
urvivors [4]. The major risk factors for nonmalignant
omplications after HCT are chronic graft-versus-
ost disease (GVHD), its treatment, and the use of
BI in the preparative regimen [5]. C
B&MTAlthough there is still some controversy regarding
he mode of delivering TBI, there has been a shift to-
ard the use of fractionated TBI (FTBI), as opposed
o single-fraction TBI (STBI), in an attempt to reduce
oxicity and improve relapse-free survival [6]. For in-
tance, some long-term complications such as cata-
acts, avascular necrosis of the bone, and hypothyroid-
sm seem more frequent in patients who receive STBI
ompared with FTBI [7-9]. Results are nevertheless
ontradictory in terms of antileukemic activity; some
tudies show better tumor control with STBI [10,11],
nd others reach the opposite conclusion [12,13].
Few articles exist on the renal consequences of
CT, although many warn about the potential toxic-
ty that could eventually lead to renal failure [14-16].
hemotherapeutic drugs, nephrotoxic antibiotics, cy-
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7losporin A (CSA), sepsis, hypotension, and concur-
ent liver disease all potentially cause acute renal fail-
re after HCT. This early renal failure is usually
eversible and does not seem to be related to the later
evelopment of radiation nephropathy [17]. This syn-
rome, also calledHCT nephropathy, has been conﬁrmed
n animal models [18] and clinical studies [19,20],
hich have revealed a direct association between TBI
ose and renal failure after HCT. However, the exact
ncidence of HCT nephropathy is unknown, ranging
etween 0.6% and 13% [21], because of a lack of
ell-designed analyses to provide cumulative inci-
ence rates and descriptions of risk factors [22].
Single doses of x-ray sufﬁcient to cause radiation
ephropathy in laboratory mice do not cause ne-
hropathy when fractionated in multiple doses [23].
e recently detected an unusually high incidence of
evere chronic renal failure (CRF) in our group of trans-
lant recipients conditioned with STBI-based regi-
ens and, therefore, decided to assess retrospectively
he risk of acute and CRF after STBI- or FTBI-based
reparative regimens. Together with this information,
e also analyzed the roles of other patient, disease,
nd posttransplantation factors in the development of
enal dysfunction.
ATIENTS AND METHODS
tudy Patients
From February 1996 to March 2004, data from
01 consecutive patients who had TBI-based prepar-
tive regimens for allogeneic HCT at the Royal Free
nd University College Hospitals were retrospectively
ollected. Because the main end point of this study
as the incidence of CRF, 52 patients who died within
months after HCT and 8 patients without sufﬁcient
ollow-up data were excluded from analysis (see be-
ow). Of these patients, 119 had their transplantation
t the Royal Free Hospital (RFH) and 122 at Univer-
ity College London Hospitals (UCLH). All patients
olunteered written informed consent in accordance
ith regulatory and institutional guidelines. Details
egarding diagnosis, disease status at transplantation,
onor type, stem cell source, preparative regimens, and
mmunosuppression after transplantation are listed in
able 1. Only 5 (2%) patients had had a previous
utologous HCT, and 8 (3%) had multiple myeloma,
disease typically associated with renal dysfunction.
one of the patients assessed in this study had a
onmyeloablative transplantation.
reparative Regimens
Chemotherapy mainly consisted of cyclophospha-
ide (120 mg/kg in 2 divided doses) alone or in
ombination with ﬂudarabine (90 mg/m2 in 3 divided
oses), alemtuzumab (100 mg in 5 divided doses), or u
6oth. Fludarabine and alemtuzumab were adminis-
ered preferentially to those patients who received T
ell–depleted (TCD) transplants to ensure engraft-
ent. According to RFH institutional guidelines, ﬂu-
arabine doses were reduced by 50% in patients with
glomerular ﬁltration rate (GFR) 60 mL/min/1.73
2, but this adjustment was not observed at UCLH.
ccasionally patients received etoposide (60 mg/kg)
r melphalan (140 mg/m2) instead of cyclophospha-
ide (Table 1).
TBI was commenced after completion of chemo-
herapy and was delivered as a single fraction of 7.5 Gy
7.5S group) in 111 patients, 12 Gy in 6 fractions (12F
roup) in 84 patients, and 14.4 Gy in 8 fractions
14.4F group) in 46 patients. Most RFH patients re-
eived STBI, whereas all UCLH patients had FTBI in
ccordance with institutional protocols. The median
ose rate was 13 cGy/min in the 7.5S group and 6
Gy/min, with a minimum 6-hour interval between
ractions, in the 12F and 14.4F groups. In vivo dosim-
try was performed during every treatment session on
he central axis and off-axis anatomic sites. In FTBI
atients, lung blocks were used to limit the lung dose
o 10 Gy. The liver and kidneys were not shielded in
ny patient.
upportive Care
All patients received standard nursing and sup-
ortive care protocols. Infection prophylaxis com-
rised itraconazole suspension 200 mg orally twice
aily; acyclovir 5 to 10 mg/kg intravenously every 8
ours; and co-trimoxazole 960 mg orally twice daily
rom day 7 to day 1, followed by aerosolized pen-
amidine 300 mg monthly until co-trimoxazole could
e resumed. Patients with neutropenic fever were treated
ith broad-spectrum antibiotics, generally meropenem
r piperacillin-tazobactam. Additional agents (teico-
lanin and aminoglycosides) were added as clinically
ndicated. Amphotericin B (1-3 mg/kg/d) was given to
atients with unexplained fever that persisted beyond
6 hours. Blood products were universally leukode-
leted and irradiated. Cytomegalovirus-seronegative
ecipients received cytomegalovirus-seronegative blood
roducts.
VHD Prophylaxis
GVHD prophylaxis was with a combination of
SA and methotrexate in unmanipulated transplants
r with CSA alone or nothing in case of TCD trans-
lants. Methotrexate was infused at a dose of 15
g/m2 on day1 and 10 mg/m2 on days3,6, and
11. Beginning on day 1, CSA was administered at
mg/kg for unmanipulated transplants or 3 mg/kg for
CD transplants. The CSA dose was adjusted to
aintain trough blood levels of 300 to 400 ng/mL in
nmanipulated transplants or 200 to 300 ng/mL in
T
o
u
p
t
i
c
d
T
l
a
e
a
p
H
p
e
s
M
a
M
(
t
G
A
C
m
B
c
p
m
a
T
S
M
M
D
M
P
D
S
G
C
G
H
cant.
Renal Failure after Allogeneic Transplantation
BCD transplants. In the absence of GVHD, the dose
f CSA was tapered from day 100. Tapering sched-
les were modiﬁed at the discretion of the attending
hysicians by disease status and activity of GVHD. In
he event of renal dysfunction or other signs of CSA-
nduced toxicity, its dose was reduced accordingly. In
ase of posttransplantation hemolytic-uremic syn-
rome/thrombocytopenic thrombotic purpura (HUS/
TP), CSA was generally substituted by mycopheno-
ate mofetil 15 mg/kg twice daily. TCD was mostly
ccomplished by adding 20 mg of alemtuzumab to
ither bone marrow or peripheral blood stem cells,
lthough CD34 selection was also used in a few
atients.
istopathology
Renal biopsy tissue was available for review in 5
atients and was processed for light, ﬂuorescence, and
lectron microscopy. In each case, parafﬁn-embedded
able 1. Patient and Transplantation Details According to TBI Dose
Patient Characteristic
Group 1
(7.5 Gy; n  111)
ex, male/female (%) 64/36
edian age, y (range) 27 (5-55)
edian follow-up, mo (range) 14.7 (3.2-65)
isease, n (%)
Acute myeloid leukemia 41 (37)
Acute lymphoid leukemia 36 (33)
Chronic myeloid leukemia 18 (16)
Non-Hodgkin lymphoma 5 (4)
Myelodysplastic syndrome 7 (6)
Multiple myeloma 2 (2)
Hodgkin disease 1 (1)
Myeloproliferative disorder 1 (1)
Chronic lymphocytic leukemia 0 (0)
edian pre-HCT GFR, mL/min (range) 115 (40-289)
rior autologous transplantation, n (%) 4 (4)
onor, n (%)
Matched related 58 (52)
Matched unrelated 33 (30)
Mismatched 20 (18)
tem cell source, n (%)
Peripheral blood stem cells 58 (52)
Bone marrow 53 (48)
rafts, n (%)
Unmanipulated 39 (35)
T-cell depleted 72 (65)
onditioning, n (%)
TBI  Cy  Alem 45 (40)
TBI  Cy  fludarabine  Alem 65 (59)
TBI  etoposide 0 (0)
TBI  melphalan 1 (1)
VHD prophylaxis, n (%)
Cyclosporin A  methotrexate 39 (35)
Cyclosporin A 32 (29)
Nothing (alemtuzumab in vivo) 40 (36)
CT indicates hematopoietic cell transplantation; GFR, glomerula
alemtuzumab; GVHD, graft-versus-host disease; NS, not signiﬁections were stained with hematoxylin and eosin, G
B&MTasson trichrome, periodic acid–Schiff, and methen-
mine silver/periodic acid–Schiff (Jones stain).
easurements, Definitions, and Statistical Analysis
Renal function was assessed by serum creatinine
SCr) concentration and estimated GFR, calculated by
he modiﬁcation of diet in renal disease equation [24]:
FR(mL ⁄min ⁄ 1.73 m2) 186.3 SCr (mg ⁄ dL)1.154
Age (y)0.203 1.212 if black,  0.742 if female
ccording to National Kidney Foundation guidelines,
RF was deﬁned as an estimated GFR of 60 mL/
in/1.73 m2 that persisted for at least 3 months [25].
ecause most patients received CSA or other cal-
ineurin inhibitors for at least 3 months after trans-
lantation, we decided to extend this period to 6
onths. However, patients who died within 6 months
fter transplantation and had an abnormally reduced
Group 2
Gy; n  84)
Group 3
(14.4 Gy; n  46)
P Value
(2 or
Kruskal-Wallis tests)
70/30 52/48 .126 (NS)
30 (9-53) 38.5 (13-57) <.001
.5 (3.3-102) 12.15 (3.3-81) .002
<.001
4 (5) 37 (81)
36 (43) 1 (2)
12 (14) 1 (2)
16 (19) 1 (2)
2 (3) 6 (13)
6 (6) 0 (0)
0 (0) 0 (0)
4 (5) 0 (0)
4 (5) 0 (0)
04 (39-286) 103 (51-177) .027
1 (1) 0 (0) .276 (NS)
.003
50 (60) 20 (44)
30 (36) 13 (28)
3 (4) 13 (28)
<.001
9 (12) 26 (82)
63 (88) 8 (18)
<.001
83 (99) 1 (2)
1 (1) 45 (98)
<.001
70 (83) 20 (44)
0 (0) 26 (56)
8 (10) 0 (0)
6 (7) 0 (0)
<.001
84 (100) 1 (2)
0 (0) 45 (98)
0 (0) 0 (0)
ion rate; TBI, total body irradiation; Cy, cyclophosphamide; Alem,(12
29
1
r ﬁltratFR for at least 3 months were also considered to
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7ave CRF. Severe CRF was deﬁned as a GFR of 30
L/min/1.73 m2, and end-stage renal failure (ESRF)
as deﬁned as a GFR of 15 mL/min/1.73 m2, the
eed for dialysis, or both (Table 2).
Cumulative incidence curves of CRF, severe CRF,
nd ESRF were estimated by considering non–renal
ailure–associated deaths as a competing risk and were
ompared by using the Lunn-McNeil approach. We
nalyzed several factors for their association with these
utcomes, including age (30 versus 30 years), pre-
ransplantation GFR (100 versus 100 mL/min/
.73 m2), disease status (ﬁrst chronic phase/ﬁrst com-
lete remission versus advanced), preparative regimen
ﬂudarabine versus no ﬂudarabine; alemtuzumab ver-
us no alemtuzumab), TBI (7.5S versus 12F versus
4.4F; S versus F), donor type (related versus unre-
ated; matched versus mismatched), GVHD prophy-
axis (CSA versus no CSA; TCD versus no TCD), and
VHD incidence (no versus yes; grades 0-II versus
II-IV). No attempt was made to evaluate the effect of
ther nephrotoxic drugs, such as aminoglycosides or
mphotericin B. Baseline characteristics were com-
ared by using the Kruskal-Wallis or Mann-Whitney
ests for continuous variables and 2 or Fisher exact
ests for categorical factors. In all statistical calcula-
ions, unadjusted P values .05 were considered sig-
iﬁcant.
ESULTS
hronic Renal Failure
The cumulative incidence of CRF was 12% at 2
ears. The median time to renal impairment was 3
onths (range, 0.3-54.5 months), and the median
eak SCr level was 205 mol/L (range, 141-745
mol/L). The median estimated GFR was 40 mL/
in/1.73 m2 (range, 10-56 mL/min/1.73 m2) at last
ollow-up or death. In 98% of CRF patients, ultra-
ound and/or computed tomographic scans were per-
able 2. Deﬁnitions of Chronic Renal Failure Adapted from the
ational Kidney Foundation Criteria [25]
Stage Description
GFR
(mL/min/1.73 m2)
1 Kidney damage with normal GFR >90
2 Mild GFR reduction 60-89
3 Moderate GFR reduction 30-59
4 Severe GFR reduction 15-29
5 ESRF <15 or dialysis
hronic renal failure was deﬁned as GFR60 mL/min/1.73 m2 for
6 months. Patients who died within 6 months after transplan-
tation but had an abnormally reduced GFR for at least 3 months
were also considered to have CRF.
FR indicates glomerular ﬁltration rate; ESRF, end-stage renal
failure.ormed to rule out an obstructive condition, and re- 1
8ults were abnormal in 2 of them (6.9%). The ﬁrst
atient was a 45-year-old acute myeloid leukemia
AML) patient who had a nephrectomy as a teenager
nd developed severe acute renal failure during AML
nduction chemotherapy. A renal biopsy performed at
hat time revealed focal segmental glomerulosclerosis
y leukemic inﬁltration. The second patient was a
1-year-old AML patient who had mild bilateral hy-
ronephrosis of no obvious cause. This last patient
ulﬁlled criteria for severe CRF but did not require
ialysis (see below).
In terms of risk factors, age at transplantation
trongly predicted the risk of CRF. The cumulative
ncidence of CRF within 2 years of transplantation
as 4% for patients 30 years of age compared with
0% for patients who were 30 years (hazard ratio
HR], 6.58; 95% conﬁdence interval [CI], 2.29-18.90;
 .001; Figure 1). In addition, patients who received
udarabine as part of their preparative regimen had a
igniﬁcantly increased risk of CRF compared with
atients who did not receive ﬂudarabine immediately
efore TBI (HR, 2.57; 95% CI, 1.19-5.52; P  .016;
igure 1). Because ﬂudarabine doses were reduced
ccording to renal function at RFH only, a hospital-
tratiﬁed analysis was performed, which revealed a
ery similar result. Finally, because CSA has been
idely reported to cause reversible renal failure [26]
nd because 34% of our CRF patients were receiving
SA at the time of the last SCr measurement, we
ecided to study only those patients not taking CSA or
ny other calcineurin inhibitor. Not surprisingly, the
esults were equivalent, and the same variables were
dentiﬁed: age at transplantation and ﬂudarabine ad-
inistration. None of these variables had a signiﬁcant
ffect on non–renal failure–associated mortality by
ompeting risk analysis.
evere and End-Stage CRF
The cumulative incidence of severe CRF and
SRF in our cohort was 3.6% at 2 years (8 of 241
atients). Two factors seemed to be signiﬁcantly
ssociated with the incidence of severe CRF and
SRF: STBI and ﬂudarabine administration (Figure
). Indeed, 7 (6.3%) of 111 patients who received
TBI qualiﬁed for severe CRF and ESRF compared
ith 1 (0.8%) of 130 patients who received FTBI
HR, 8.59; 95% CI, 1.06-69.84; P  .044). Also, 7
7.5%) of 93 patients who received ﬂudarabine in
heir preparative regimens fulﬁlled criteria for se-
ere CRF and ESRF, compared with 1 (0.7%) of
48 patients who did not receive it (HR, 11.93; 95%
I, 1.47-97.02; P  .020). It is interesting to note
hat the 2-year non–renal-associated mortality in
he STBI group was signiﬁcantly higher than in the
TBI group (31% versus 9%; HR, 3.844; 95% CI,
.87-7.90; P  .001; Figure 2).
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BThe characteristics of the 8 patients with severe
RF and ESRF are shown in Table 3. It is inter-
sting to note that the only patient with severe CRF
ho received FTBI as part of his preparative regi-
en had bilateral hydronephrosis, which makes it
ifﬁcult to assess the contribution of TBI or other
actors in his CRF. The remaining 7 patients all
eceived STBI, and 6 (86%) of 7 received ﬂudara-
ine as part of their preparative regimens. Five of
hese patients presented with clinical and laboratory
eatures suggestive of HUS/TTP at a median of 6.6
onths after transplantation (range, 2.3-8.2
onths). The hematologic abnormalities (ie, ane-
ia, thrombocytopenia, and an increased number of
ragments in the peripheral blood) generally re-
ponded to CSA withdrawal with or without plasma
xchanges, but the renal failure slowly progressed to
evere CRF or ESRF. Renal biopsies performed in 4
f these 5 patients were suggestive of thrombotic
icroangiopathy/radiation nephropathy. Light mi-
igure 1. Cumulative incidence plots of chronic renal failure (CRF
t transplantation and (B) ﬂudarabine administration. CRF was deﬁn
months [25].roscopy showed irregularity of capillary loop out- b
B&MTines, mesangiolysis, and mesangial hypercellularity,
nd when silver stains were used, the typical double
ontours became apparent. Ultrastructural examina-
ion revealed subendothelial widening, new basement
embrane formation, and foot process fusion [27,28].
The other 2 patients with severe CRF had a
ifferent clinical evolution. The ﬁrst was a 48-year-
ld man with a low pretransplantation GFR (55
L/min/1.73 m2) who received a transplant from an
LA-mismatched unrelated donor and developed
cute GVHD. He then had CSA-induced renal fail-
re but never recovered after CSA withdrawal. The
econd patient was a 40-year-old man who devel-
ped progressive renal failure 3 months after trans-
lantation of no obvious cause. A renal biopsy sam-
le was consistent with severe tubulopathy, showing
arked ﬂattening and disruption of tubular epithe-
ial cells and lymphocytic inﬁltration with clusters
f neutrophils. It is interesting to note that no
lomerular abnormalities were suggestive of throm-
n–renal failure–associated mortality (NRFM) according to (A) age
n estimated GFR of60 mL/min/1.73 m2 that persisted for at least) and no
ed as aotic microangiopathy/radiation nephropathy.
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8ISCUSSION
CRF after HCT has been long recognized as related
o the TBI used in the preparative regimen [29]. TBI is
sually preceded by cytotoxic chemotherapy, which po-
entiates the effects of radiation [30]. Clinically, when
igure 2. Cumulative incidence plots of severe chronic renal failure
ortality (NRFM) according to (A) total body irradiation fractionati
s an estimated GFR of 30 mL/min/1.73 m2 that persisted for at
able 3. Characteristics of Patients with Severe CRF or ESRF
Age (y) Donor
GFR
(mL/min/1.73 m2) FLUD TBI Median TT
51 mMUD 74 Yes F 0.
37 MUD 77 Yes S 7.
36 MRD 94 Yes S 6.
37 MRD 101 Yes S 8.
30 mMUD 170 Yes S 4
53 MRD 88 No S 2.
48 mMUD 55 Yes S 0.
40 MRD 104 Yes S 3
MUD indicates mismatched unrelated donor; MUD, matched un
rate before transplantation; FLUD, ﬂudarabine; TBI, total body
GVHD, graft-versus-host disease; TTP, thrombotic thrombocy
thrombotic microangiopathy/radiation nephropathy.
0SA and other nephrotoxic drugs have been ruled out as
he cause of CRF, the disorder may be labeled as HCT
ephropathy, a form of radiation nephropathy [21]. This
ondition typically presents 8 to 12 months after HCT
s hypertension, progressive azotemia, and dispropor-
), end-stage renal failure (ESRF), and non–renal failure–associated
(B) ﬂudarabine administration. Severe CRF and ESRF were deﬁned
months [25].
o) GVHD TTP US/CT Biopsy Results Dialysis
Yes No Hydronephrosis — No
No Yes Normal TMA/RN No
No Yes Normal TMA/RN Yes
Yes Yes Normal TMA/RN Yes
No Yes Normal — Yes
No Yes Normal TMA/RN Yes
Yes No Normal — No
No No Normal Tubulopathy Yes
donor; MRD, matched related donor; GFR, glomerular ﬁltration
ion; F, fractionated; S, single fraction; TTRF, time to renal failure;
c purpura; US/CT, ultrasound/computed tomography; TMA/RN,(SCRF
on andRF (m
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Renal Failure after Allogeneic Transplantation
Bionately severe anemia, thus resembling the radiation
ephritis described 50 years ago as a complication of
bdominal radiotherapy for seminoma [31]. HCT ne-
hropathy may result in a substantial comorbidity due to
rogressive renal function loss, which frequently re-
uires dialysis or kidney transplantation [32]. Because
RF affects only a few patients who receive TBI, addi-
ional factors may inﬂuence the development of HCT
ephropathy. TBI dose, GVHD development [19], the
bsence of a renal shielding during TBI, and angioten-
in-converting enzyme gene polymorphisms [33] have
een suggested as possible risk factors for renal dysfunc-
ion after HCT. In this study, CRF was deﬁned as a
ersistent GFR 60 mL/min/1.73 m2 because those
atients are at an increased risk of further renal function
oss, cardiovascular disease, hospitalization, and death
25,34]. However, most CRF patients are asymptom-
tic, and therefore other clinically relevant outcomes,
uch as severe CRF and ESRF, were also assessed. In
his analysis, age and the administration of ﬂudarabine
s part of the preparative regimen were signiﬁcant risk
actors for CRF, whereas TBI fractionation also de-
ermined the incidence of severe CRF and ESRF.
FTBI was originally devised to reduce acute and
ong-term toxicity after HCT [6,10,12]. Indeed, most
cular, endocrine, and skeletal long-term complica-
ions seem to be more frequent in patients who receive
TBI as opposed to FTBI [5,7-9]. Also, large retro-
pective studies suggest that the incidence of solid
umors after transplantation depends on the total cu-
ulative dose administered and its fractionation [2,3].
owever, FTBI has never proved to prevent CRF,
ainly because very few institutions currently use
TBI. In murine models, single doses of radiation able
o cause radiation nephropathy are less toxic when
ractionated into multiple doses [23]. This increased
tolerance” of radiation with increasing fractionation
s probably due to repair of sublethal radiation damage
etween fractions and to the reduced dose rates used
n FTBI (6 cGy/min as opposed to 13 cGy/min). In
his study, TBI fractionation had a signiﬁcant effect
n the incidence of severe CRF and ESRF, which
onﬁrmed our hypothesis that STBI may have a del-
terious effect on renal function. Finally, we suspect
hat STBI is associated with a higher incidence of
osttransplantation HUS/TTP, as was the case in our
tudy (data not shown). This is intriguing because the
arget cells for both HUS/TTP and HCT nephropa-
hy are the endothelium of arterioles and capillaries,
nd the resulting histopathologic picture is identical.
ndeed, these conditions seem to be associated, be-
ause the more severe cases of HCT nephropathy
resent much like HUS/TTP [19]. However, this
ypothesis could not be formally tested because the
iagnostic criteria for HUS/TTP were not homoge-
eous across the entire cohort of patients.The effect of age on the incidence of renal failure t
B&MTs more controversial. Currently, 5% to 20% of adults
ho undergo HCT develop CRF [21], whereas sev-
ral studies have reported higher incidences of CRF in
hildren after allogeneic HCT, ranging from 28% to
5% [35-37]. In children, CRF seems to be less fre-
uent with reduced TBI doses (5-8 Gy), which also
ecrease the incidence of HUS/TTP [37], but no
ormal comparison has ever been made. In addition, a
ifferent study performed in children with acute lym-
hoid leukemia reported a CRF rate of only 3%, con-
luding that pretransplantation chemotherapy rather
han young age was the major contributing factor to
he lower tolerance of children to TBI [38]. Our study
evealed that age at transplantation 30 years was
igniﬁcantly associated with a higher risk of CRF. It
ay be argued that older age at transplantation is usually
ssociated with a lower pretransplantation GFR, as was
he case (P .001; Fisher exact test), but age remained
igniﬁcant after adjustment for GFR (P .002), which
onﬁrmed its independent effect on the incidence of
RF.
Probably the most interesting ﬁnding of this study
s the unexpected effect of ﬂudarabine on the inci-
ence of CRF. It has been previously reported that
udarabine enhances radiation-induced damage in both
urine [39] and human [40] tumors. Upon cell entry
nd phosphorylation, the active metabolite ﬂudara-
ine triphosphate (F-ara-ATP) inhibits several key
nzymes involved in DNA synthesis and repair. Po-
ential mechanisms for ﬂudarabine-induced radiosen-
itization include repair inhibition of radiation-in-
uced chromosome breaks, cell synchronization to a
ore radiosensitive cell-cycle phase, S-phase cell loss
y apoptosis, and inhibition of cell repopulation [41].
onversely, the effectiveness of this combination de-
ends on the ﬂudarabine dose and the time interval
etween ﬂudarabine administration and irradiation;
he combination is particularly effective when irradi-
tion is delivered as a single fraction at least 24 hours
fter drug treatment [39,42]. On the basis of the sim-
larities between these tumor models and our TBI-
ased preparative regimens, we hypothesize that ﬂu-
arabine may have a radiosensitizing effect on the
lomerular endothelium. However, this possible ra-
iosensitizing effect must be closely related to the TBI
ose, because the Seattle group recently used ﬂudara-
ine 90 mg/m2 followed by STBI (2 Gy) as a prepar-
tive regimen for allogeneic HCT and did not notice
high incidence of renal dysfunction [43].
In conclusion, this analysis provides data on the
ncidence and severity of CRF after transplantation in
n unselected population of HCT recipients. The inci-
ence of CRF was associated with age and ﬂudarabine
dministration. Furthermore, STBI seemed to be par-
icularly deleterious because it signiﬁcantly increased
he incidence of severe CRF and ESRF. Therefore, a
echnique that delivers a maximum dose of 12 Gy in 6
81
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8ractions, preferably without ﬂudarabine, could be
onsidered “renally safe” for most patients and could
ecrease the development of CRF. However, these
onclusions should be regarded as preliminary in view
f the retrospective and nonrandomized nature of this
nalysis. Indeed, the potential biases inherent to these
tudies should be kept in mind when the results are
ssessed.
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